102 related articles for article (PubMed ID: 7882456)
1. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Rigas JR; Francis PA; Miller VA; Tong WP; Roistacher N; Kris MG; Orazem JP; Young CW; Warrell RP
Cancer Chemother Pharmacol; 1995; 35(6):483-8. PubMed ID: 7882456
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
Rigas JR; Tong WP; Kris MG; Orazem JP; Young CW; Warrell RP
Cancer Res; 1992 Dec; 52(23):6619-23. PubMed ID: 1423306
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
Conley BA; O'Hara S; Wu S; Melink TJ; Parnes H; Pardoe E; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 1995; 37(1-2):139-49. PubMed ID: 7497583
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.
Miller VA; Rigas JR; Tong WP; Reid JR; Pisters KM; Grant SC; Heelan RT; Kris MG
Cancer Chemother Pharmacol; 1997; 40(5):415-8. PubMed ID: 9272118
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC).
Bekaii-Saab TS; Mortazavi A; Hicks LG; Zalupski M; Pelley RJ; Chan KK; Kraut EH
Invest New Drugs; 2006 Jul; 24(4):343-6. PubMed ID: 16446986
[TBL] [Abstract][Full Text] [Related]
6. Chloroquinoxaline sulfonamide: a sulfanilamide antitumor agent entering clinical trials.
Fisherman JS; Osborn BL; Chun HG; Plowman J; Smith AC; Christian MC; Zaharko DS; Shoemaker RH
Invest New Drugs; 1993 Feb; 11(1):1-9. PubMed ID: 8349430
[TBL] [Abstract][Full Text] [Related]
7. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
[TBL] [Abstract][Full Text] [Related]
14. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
16. [A phase I study on a weekly schedule of DWA2114R].
Niitani H; Fukuoka M; Furusawa M; Tamura M; Hasegawa K; Kurita Y; Ariyoshi Y; Matsunaga T; Kumoi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1027-32. PubMed ID: 1626938
[TBL] [Abstract][Full Text] [Related]
17. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Curtis KK; Hartney JT; Jewell RC; Park JW; Lebowitz PF; Griffin PP; Borad MJ; Fitch TR; Northfelt DW
J Clin Pharmacol; 2010 Mar; 50(3):268-75. PubMed ID: 19808951
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
19. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
Harman GS; Craig JB; Kuhn JG; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J; Tuttle RL; Lucas VS
Cancer Res; 1988 Aug; 48(16):4706-10. PubMed ID: 3396016
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
